文献速递膀胱癌与上尿路尿路上皮癌

选择性T1非肌层浸润性膀胱癌患者可安全省略二次电切:前瞻性HuNIRe试验结果

Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non-muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial.
PubMed 文献 · Eur Urol Oncol · 2026-02-07

HuNIRe前瞻性观察性多中心试验纳入90例T1 NMIBC患者,初始TUR完整后根据3-4周尿细胞学和4-6周膀胱镜结果选择性行ReTUR。71%患者避免ReTUR直接BCG灌注,2年RFS 69%、PFS 91%,有无ReTUR组间无显著差异,支持反应引导的个体化策略。

要点

  • 完整TUR后经尿细胞学和膀胱镜筛选,71%的T1 NMIBC患者可安全省略ReTUR。
  • 选择性ReTUR组与常规ReTUR组2年RFS和PFS无显著差异。
  • 该策略需谨慎解读,因随访时间较短(中位26个月)。

核心结论

  • 在初始TUR完整的T1 NMIBC患者中,基于早期尿细胞学和膀胱镜的反应引导策略可避免71%的ReTUR,且2年肿瘤学结局与常规ReTUR相当。

研究设计与样本

  • 前瞻性、观察性、多中心HuNIRe试验,2020至2024年纳入90例T1 NMIBC患者。
  • 完整TUR后3-4周行尿细胞学、4-6周行膀胱镜,仅细胞学阳性(巴黎系统3-6)或膀胱镜发现病变者行ReTUR,否则直接BCG诱导治疗。

主要发现

  • 71%(n=64)患者避免ReTUR并直接接受BCG治疗,29%(n=26)需ReTUR,ReTUR时无患者上调为MIBC。
  • 中位随访26个月,全队列2年RFS为69%、PFS为91%。
  • 有无ReTUR组间RFS(p=0.9)和PFS(p=0.6)无显著差异。
  • HuNIRe队列与常规ReTUR回顾队列的2年RFS(74% vs 74%)和PFS(91% vs 92%)相当。

关键数值与推荐

  • 尿细胞学阳性定义为巴黎系统3-6。
  • ReTUR指征:尿细胞学阳性或膀胱镜检出病变。

临床怎么用

  • 对初始TUR完整的T1 NMIBC患者,可考虑以早期尿细胞学和膀胱镜评估替代全部常规ReTUR。
  • 细胞学阴性且膀胱镜无病变者可直接行BCG诱导治疗,避免不必要的二次手术。

局限性

  • 随访时间较短(中位26个月),肿瘤学结局需谨慎解读。
  • 样本量较小(90例),为前瞻性观察性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Current European Association of Urology guidelines universally recommend a second transurethral resection (ReTUR) for all T1 non-muscle-invasive bladder cancer (NMIBC) cases. However, ReTUR is an invasive and costly procedure that is often negative for residual disease, and may represent overtreatment in appropriately selected patients who have undergone complete initial TUR. Our aim was to report 2-yr oncological outcomes and confirm the safety of a novel, response-guided strategy with selective ReTUR for patients with T1 NMIBC. METHODS: The prospective, observational, multicenter HuNIRe trial enrolled patients with T1 NMIBC from 2020 to 2024. Patients with complete TUR underwent urine cytology at 3-4 wk and cystoscopy at 4-6 wk. ReTUR was performed only if cytology was positive (Paris system 3-6) or disease was detected on cystoscopy; otherwise, patients proceeded directly to bacillus Calmette-Guérin (BCG) induction therapy. The primary endpoints were 2-yr recurrence-free survival (RFS) and progression-free survival (PFS). Secondary endpoints included comparison of outcomes between the groups with and without ReTUR, and between the overall HuNIRe cohort and a retrospective cohort of patients with T1 NMIBC who underwent routine ReTUR. Kaplan-Meier estimates and the log-rank test were used for survival analysis. KEY FINDINGS AND LIMITATIONS: A total of 90 patients were prospectively enrolled. The protocol successfully avoided ReTUR in 71% (n = 64) of patients, who proceeded directly to BCG therapy. Only 29% (n = 26) of the patients required ReTUR according to early evaluation; importantly, no patient was upstaged to MIBC at ReTUR. After median follow-up of 26 mo, 2-yr survival rates for the entire cohort were 69% for RFS and 91% for PFS. There were no significant differences between the groups with and without ReTUR in RFS (p = 0.9) or PFS (p = 0.6). Oncological outcomes were also comparable between the HuNIRe cohort and a retrospective cohort that underwent routine ReTUR (2-yr RFS: 74% vs 74%; 2-yr PFS: 91% vs 92%). CONCLUSIONS AND CLINICAL IMPLICATIONS: Results from the HuNIRe trial confirm that a risk-adapted approach to ReTUR in selected patients with T1 NMIBC after complete initial TUR is feasible, although oncological outcomes should be interpreted with caution owing to the short follow-up. This strategy spared 71% of patients from ReTUR, and could support a tailored, response-guided approach rather than the blanket guideline recommendation for ReTUR.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Contieri R, Paciotti M, Uleri A, et al. Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non-muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial. Eur Urol Oncol. 2026. PMID: 41654427. doi:10.1016/j.euo.2026.01.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。